GlassScriptPhysician profile
Arta Farshidi
NPI 1942491436
$2,008.13
in general payments reported to CMS, 2019-2025
21 companies · $449 in 2025
The $449 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $380 · 2020: $170 · 2021: $163 · 2022: $206 · 2023: $247 · 2024: $393 · 2025: $449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,089.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,088.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $390.17 | 2019-2025 | |
| Merz North America, INC. | $282.10 | 2019-2024 | |
| Arcutis Biotherapeutics, INC. | $243.76 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $155.76 | 2019-2025 | |
| Galderma Laboratories, L.P. | $135.46 | 2019-2024 | Aklief |
| Biofrontera INC. | $121.46 | 2024-2025 | Xepi, Bf-Rhodoled, Rhodoled Xl |
| Organon LLC | $81.79 | 2025 | Vtama |
| Leo Pharma INC. | $73.44 | 2019-2025 | Anzupgo |
| Genzyme Corporation | $71.86 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.98 | 2022-2024 | Spevigo |
| Ucb, INC. | $65.37 | 2024-2025 | Bimzelx |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $53.65 | 2019-2022 | |
| Amgen INC. | $49.79 | 2025 | Otezla, Otezla |
| Abbvie INC. | $45.19 | 2019-2025 | |
| Incyte Corporation | $44.95 | 2022-2024 | Opzelura |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $35.45 | 2023-2024 | Vtama |
| Biowound Solutions, INC. | $22.40 | 2025 | Bio-Connekt |
| Dermira, INC. | $22.04 | 2020 | |
| Verrica Pharmaceuticals INC. | $18.09 | 2024 | Ycanth |
| Medline Industries LP | $17.22 | 2019 | |
| Epi Health, LLC | $9.20 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arta Farshidi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.